---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001956"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:57:11.829442+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclerion reports FY2021 net loss $51.6M; MELAS topline data expected Q2 2022

## Summary
- Net loss $51.6M for FY2021 vs $77.8M in FY2020; cash $54M at Dec 31, 2021.
- R&D expense $37.6M (down from $56.4M); G&A $20.6M (down from $28.8M).
- Phase 2a MELAS trial enrollment closed; topline data expected in Q2 2022.
- Phase 1b CIAS trial enrollment ongoing; topline expected H2 2022; Phase 2a ADv trial initiated.
- Bruce Kinon appointed VP Clinical Development; collaboration with Ariana Pharma for AI biomarker discovery.

## SEC filing metadata
- accession: 0000950170-22-001956
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001956/0000950170-22-001956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022001956/cycn-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001956
- JSON: https://secwatch.observer/filing/0000950170-22-001956.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.